FDA-Approved Autograft Sparing Device for National Preparedness
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Health And Human Services (HHS), specifically the OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE (BARDA), has issued an Award Notice for an FDA-Approved Autograft Sparing Device for National Preparedness. This award aims to enhance national preparedness against large burn mass casualty incidences (BMCI) by providing advanced treatment solutions. The award date is April 13, 2026, with the place of performance in Washington, DC, United States.
Scope of Work
This award focuses on securing an FDA-approved autograft-sparing device. The device is intended to reduce the amount of autograft needed for wound closure in deep partial and full thickness burn injuries, particularly in mass casualty scenarios. The goal is to provide rapid and effective care, reduce donor site morbidity, and be compatible with current procedures for easy integration. Advantageous features include additional indications for full thickness skin defects due to traumatic injury, addressing other injuries that may result from a mass casualty incident.
Contract & Timeline
- Type: Award Notice
- Set-Aside: None specified
- Award Date: April 13, 2026
- Product/Service Code: Q523 (Surgery Services)
Additional Information
This award addresses the challenges of providing definitive burn care in resource-strained environments following mass casualty events, where traditional autografting is labor-intensive, time-consuming, and poses additional risks to patients.